Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301356 | 0.93 | ELANE (0.64) | ELANEP2RX3 | |
| SCHEMBL6557678 | 0.90 | ELANE (0.60) | ELANENPC1RAB9AP2RX3CTRC | |
| SCHEMBL7296453 | 0.87 | ELANE (0.64) | ELANENPC1RAB9AP2RX3 | |
| SCHEMBL6558195 | 0.86 | ELANE (0.55) | ELANEP2RX3CTRC | |
| SCHEMBL6557667 | 0.85 | ELANE (0.63) | ELANE | |
| SCHEMBL6556313 | 0.85 | ELANE (0.55) | ELANE | |
| SCHEMBL6556275 | 0.85 | ELANE (0.57) | ELANEP2RX3CTRC | |
| SCHEMBL6085435 | 0.84 | ELANE (0.67) | ELANENPC1RAB9ACTRC | |
| SCHEMBL6557643 | 0.84 | ELANE (0.64) | ELANE | |
| SCHEMBL6558300 | 0.84 | ELANE (0.63) | ELANEP2RX3CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015223-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050054643-A1 | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | disclosed |
| US-20040116430-A1 | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-6750342-B1 | INHIBITORS OF SERINE PROTEASES; ANTICOAGULANT | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-6653316-B1 | Coronary artery and cerebrovascular diseases | PHARMACIA CORPORATION | 2003-11-25 | — | — | US | disclosed |
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO., LTD. | 2003-08-14 | — | — | US | disclosed |
| US-6534658-B1 | Intermediates for producing pharmaceuticals | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | disclosed |
| EP-1197489-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-1162199-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054643-A1 | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, SERPINC1 | ELANE 182/4885NPC1 3466/4885RAB9A 3570/4885 |
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | OXA1L, CYP1B1, OXER1 | ELANE 4189/4885NPC1 4593/4885RAB9A 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.